Exploring the effect of tumor reduction surgery on the prognosis of upper tract urothelial carcinoma patients with metastasis

doi:10.3969/j.issn.1006-7795.2024.02.023

Abstract

Abstract: Objective To explore the effect of tumor reduction surgery on the prognosis of upper urinary tract urothelial cancer patients with distant metastasis. Methods The clinical data of upper urinary tract urothelial cancer patients with distant metastasis were screened in SEER database from January 2010 to December 2015. According to whether tumor reduction surgery was performed or not, the patients were divided into two groups： tumor reduction operation group and non-tumor reduction operation group. Univariate and multivariate Cox proportional hazard regression models were used to analyze the prognostic factors related to the survival of upper urinary tract urothelial cancer patients with distant metastasis. The survival curve was drawn by Kaplan-Meier method to analyze the survival condition of each group. Results A total of 238 patients were included in this study, 157 patients underwent tumor reduction surgery and 81 patients did not. The overall baseline was relatively stable. Cox univariate analysis showed that tumor reduction surgery, chemotherapy, liver metastasis were independent risk factors for overall survival（ OS）, while tumor reduction surgery and chemotherapy were independent risk factors for cancer special survival（CSS）. Kaplan-Meier curve showed that tumor reduction surgery, chemotherapy and liver metastasis were closely related to OS, while tumor reduction surgery, chemotherapy and liver metastasis were closely related to CSS. Conclusion For patients with upper urinary tract urothelial carcinoma with distant metastasis, tumor reduction surgery can significantly improve the prognosis. Tumor reduction surgery, chemotherapy, and liver metastasis are independent factors affecting the overall survival outcome. Tumor reduction surgery and chemotherapy are independent factors affecting the cancer special survival outcome.

Key words: upper tract urothelial carcinoma, metastasis, reduction surgery, prognosis, SEER

CLC Number:

R737

Zhao Yu, Zhang Rongjie, Chen Yuanhao, Li Gao, Jiao Binbin, Zhang Xin. Exploring the effect of tumor reduction surgery on the prognosis of upper tract urothelial carcinoma patients with metastasis[J]. Journal of Capital Medical University, 2024, 45(2): 340-347.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2024.02.023

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2024/V45/I2/340

References

［1］ Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update［J］. Eur Urol, 2021, 79(1): 62-79.
［2］ Rouprêt M, Seisen T, Birtle A J, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update［J］. Eur Urol, 2023, 84(1): 49-64.
［3］ Favaretto R L, Shariat S F, Chade D C, et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center［J］. Eur Urol, 2010, 58(4): 574-580.
［4］ Cheaib J G, Claus L E, Patel H D, et al. Site of metastatic recurrence impacts prognosis in patients with high-grade upper tract urothelial carcinoma［J］. Urol Oncol, 2021, 39(1): 74.e9-74.e16.
［5］ Soria F, Shariat S F, Lerner S P, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)［J］. World J Urol, 2017, 35(3): 379-387.
［6］ Davaro F, May A, McFerrin C, et al. Chemotherapy increases survival and downstaging of upper tract urothelial cancer［J］. Can J Urol, 2019, 26(5): 9938-9944.
［7］ Margulis V, Shariat S F, Matin S F, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration［J］. Cancer, 2009, 115(6): 1224-1233.
［8］ Raman J D, Messer J, Sielatycki J A, et al. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005［J］. BJU Int, 2011, 107(7): 1059-1064.
［9］ Uprety D, Bista A, Smith A L, et al. Cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in the targeted therapy era［J］. Anticancer Res, 2018, 38(5): 3013-3018.
［10］ Culp S H, Schellhammer P F, Williams M B. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study［J］. Eur Urol, 2014, 65(6): 1058-1066.
［11］ Flanigan R C, Salmon S E, Blumenstein B A, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer［J］. N Engl J Med, 2001, 345(23): 1655-1659.
［12］ Mickisch G H, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial［J］. Lancet, 2001, 358(9286): 966-970.
［13］ Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study［J］. J Urol, 2015, 193(3): 832-838.
［14］朱刚, 张凯. 原发灶减瘤根治性前列腺切除术治疗骨转移前列腺癌患者的现状及展望(附光盘)［J］. 现代泌尿外科杂志, 2017, 22(3): 162-164.
［15］ Comen E, Norton L, Massagué J. Clinical implications of cancer self-seeding［J］. Nat Rev Clin Oncol, 2011, 8(6): 369-377.
［16］ Kaplan RN, Rafii S, Lyden D. Preparing the “soil”: the premetastatic niche［J］. Cancer Res, 2006, 66(23): 11089-11093.

[1]	iang Yan, Zhao Xuanyu, Sui Feng. Identifying diagnostic gene biomarkers of moderate or severe endometriosis [J]. Journal of Capital Medical University, 2024, 45(2): 322-332.
[2]	Xu Jingxing, Zhou Quan, Ying Jianming. Recent progress on immunotherapy for tumor microenvironment of triple negative breast cancer [J]. Journal of Capital Medical University, 2023, 44(5): 882-888.
[3]	. Oncologic and functional outcomes after laparoscopic radical prostatectomy:10-years follow-up [J]. Journal of Capital Medical University, 2023, 44(3): 424-432.
[4]	Zhu Guangyi, Wang Runjin, Xiong Tianyu, Ye Xiaobo, Liu Zhanliang, Cao Fang, Lin Zhemin, Niu Yinong. Analysis of risk factors for second primary malignancies after radical prostatectomy for non-metastatic prostate cancer [J]. Journal of Capital Medical University, 2023, 44(3): 433-438.
[5]	Wang Runjin, Ye Xiaobo, Zhang Yudong, Zhu Guangyi, Yang Kun, Niu Yinong. Effect of different invasion patterns on the prognosis of patients with T3a renal cell carcinoma [J]. Journal of Capital Medical University, 2023, 44(3): 439-448.
[6]	Zhang Yudong, Wei Houyi, Wang Runjin, Jiang Mingxin, Yang Kun, Wang Mingshuai, Wasilijiang Wahafu, Song Liming, Jin Mulan, Xing Nianzeng, Niu Yinong. Prognostic significance of the controlling nutritional status (CONUT) score in patients with bladder cancer treated with radical cystectomy and ileal conduit [J]. Journal of Capital Medical University, 2023, 44(3): 449-456.
[7]	Xiong Tianyu, Niu Yinong. Mechanism of periprostatic adipose tissue affecting the development of prostate cancer [J]. Journal of Capital Medical University, 2023, 44(3): 457-462.
[8]	Yang Yifan, Wang Yamei. Expression and mechanism of apoptosis-inducing factor 2 gene in breast cancer [J]. Journal of Capital Medical University, 2023, 44(2): 248-257.
[9]	Wang Wenwen, Cai Yu, Jia Shuangshuang, Zhai Jianjun. Relationship between kinesin family proteins 2C and chemoresistance in ovarian cancer [J]. Journal of Capital Medical University, 2023, 44(1): 143-147.
[10]	Liu Qun, Li Lina, Liu Jian, Miao Jinwei. SOX4 mediates TGF-β1 induced epithelial-mesenchymal transition to promote invasion and metastasis of ovarian cancer [J]. Journal of Capital Medical University, 2022, 43(3): 336-342.
[11]	Tian Ming, Kong Qiu, Hou Xiaoxiao, Miao Jinwei. Clinicopathological analysis of benign and malignant struma ovarii [J]. Journal of Capital Medical University, 2022, 43(3): 343-349.
[12]	Zhao Yue, Ruan Xiangyan, Cheng Jiaojiao, Gu Muqing, Xu Xin, Wang Yuejiao. Breast cancer pathological diagnosis reveals correlation between progesterone receptor membrane component 1 and clinicopathological parameters [J]. Journal of Capital Medical University, 2022, 43(3): 350-356.
[13]	Jiang Mingxin, Su Yao, Xiong Tianyu, Ye Xiaobo, Jin Song, Xing Nianzeng, Jin Mulan, Yang Mingfu, Niu Yinong. The outcome of cytoreductive radical prostatectomy for prostate cancer patients with bone metastasis [J]. Journal of Capital Medical University, 2021, 42(6): 967-972.
[14]	Wang Mingshuai, Xiong Tianyu, Jiang Mingxin, Qian Xiaosong, Wang Sihao, Cui Yun, Niu Yinong. The effect of modified apical dissection and periurethral structure preservation in the immediate continence recovery after laparoscopic radical prostatectomy [J]. Journal of Capital Medical University, 2021, 42(6): 973-977.
[15]	Ye Xiaobo, Xiong Tianyu, Cui Yun, Wang Mingshuai, Yang Hui, An Zhuoling, Niu Yinong. Efficacy of abiraterone acetate combined with prednisone in the treatment of castration-resistant prostate cancer [J]. Journal of Capital Medical University, 2021, 42(6): 978-985.